Terminology Quiz 1 Flashcards
120-day safety report
amendment to a NDA containing a safety update due 120 days after the NDA is filed
30-day hold
time period between filing a protocol under an IND and FDA approval to proceed with enrollment. Also the time period between when a company submits an IND and when it can initiate a protocol. This time line may be extended if FDA does not agree with the proposed protocol
505(b)(2)
A form of NDA that incorporates data without a right of reference and can rely on published literature, previously approved NDA, of “Bridging Studies” or the combination of all three. Cannot file if eligible for an ANDA. Used for new salts, dosage forms, routes of administration, etc.
510(k)
i. traditional 510(k): a premarket notification submitted to FDA to demonstrate that the medical device to be marketed is as safe and effective or “substantially equivalent” to a legally marketed device.
ii. special 510(k): for use where device notifications neither affect the intended use nor alter its fundamental scientific technology.
iii. abbreviated 510(k): submission based upon guidance document(s), special controls or standards
AAAS
American Association for the Advancement of Science
AABB
American Association of Blood Banks
AADA
Abbreviated Antibiotic Drug Application; primarily used for generics on the 505(j) form
AAPS
American Association of Pharmaceutical Scientists
ACS
American Chemical Society
ACE
Adverse Clinical Event; any unexpected, unfavorable event that is may or may not be related to the use of the investigational drug
Action letter
official communication from FDA informing NDA/BLA sponsor of an agency decision
Active ingredient
any drug component intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure or any function of the body of man or others
ADE
Adverse drug event or adverse drug experience
ADME
Absorption, distribution, metabolism and excretion; essential to the measuring of pharmacokinetics
ADR
Adverse drug reaction; is any unexpected adverse drug experience not listed in the drug product’s current labeling
Adulterated
product containing any filthy, putrid or decomposed substance
AE
adverse event; any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and that does not necessarily have a casual relationship with this treatment
AERS
adverse event reporting system
AFDO
Association of Food and Drug Officials
AHCPR
Association for Health Care Policy and Research
AIP
Application Integrity Policy; FDA’s approach to reviewing applications that may be affected by wrongful acts that raise significant questions regarding data reliability
amendment
additions or changes to an ANDA, NDA, PMA or PMA supplement still under review
ANADA
Abbreviated New Animal Drug Application; used for generic animal drugs
ANDA
Abbreviated New Drug Application; used for generic drugs
ANDA sections
the sections that the ANDA must include are:
- regulatory and administrative requirements, exclusivity
- chemistry
- manufacturing
- controls
- labeling
- testing
- bioequivalence
Annual report
an annual periodic report or progress report that must be submitted to the FDA
APhA
American Pharmaceutical Association
APHIS
Animal and Plant Health Inspection Service
API
Active Pharmaceutical Ingredient. Any substance or mixture of substances intended to be used in the manufacture of a medicinal product that, when used in the production of a drug, becomes an active ingredient of the medicinal product
Approved
FDA designation given to drugs, biologics and medical devices that have been granted marketing approval
AQL
Acceptable Quality Level; a quality standard that allows for a per-specified number of defects
ASQ
American Society for Quality (formerly ASQC)
ASR
Analyte Specific Reagents
BACPAC
Bulk Actives Chemical Post Approval Changes
Banned Devices
Device presenting a substantial deception, unreasonable risk of injury or illness, or unreasonable direct and substantial danger to public health
BATF
Bureau of Alcohol, Tobacco, and Firearms
BIMO
Bioresearch Monitoring Program
BIO
Biotechnology Industry Organization
Batch Release Requirements (Drugs)
The quality control team must inspect all documents and data to ensure that the product may be distributed before it can be released from the manufacturing plant
Biologic
Any virus, therapeutic serum, toxin, antitoxin or analogous product applicable to the prevention, treatment or cure of diseases or injuries to man